Pure Global
NCT05902494

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression
Seagen Inc.·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Study type
Observational
Sponsor & location
Primary sponsor
Seagen Inc.
Location
San Francisco,Sioux Falls, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jun 29, 2023
End date
Feb 29, 2024
Enrollment
500 participants
Primary outcome

Real-world Objective Response Rate (rwORR) per modified response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)

Summary

This study is being done to learn about urothelial cancers that make HER2 and how that
 affects treatment choices for participants with urothelial cancer. During this study, the
 medical and health records of participants will be reviewed to learn more about their health.
 
 Participants will have urothelial cancer that has grown in the body near where it started
 (locally advanced) and cannot be removed (unresectable) or has spread through the body
 (metastatic).

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05902494
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05902494 through Pure Global AI's free database. This phase not specified trial is sponsored by Seagen Inc. and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.